An early stage fund based in Israel is investing in private companies developing pharmaceuticals only. The firm invests in early stage projects, preferably with PoC validation, and supports companies from venture creation to Series A. The firm’s average ticket size is $15M along the lifespan of the company and comes in the form of straight equity. The firm seeks board representation and is a very active investor, helping guide the company’s development and strategy. The firm is fundamentally science-driven, invests globally and may lead or co-invest. The firm has no targeted number of investments per year.
The firm’s mother company recently launched a late stage fund that seeks investments in private companies developing pharmaceuticals which raise Series B and up to Crossover round/IPO.
Both early-stage and late stage funds are open to both pre-clinical and clinical stage companies and are agnostic to technology type and indication. The firm has a specific interest in immuno-oncology, gene therapy, RNA/DNA based therapy and orphan or unmet medical need. The firm is only interested in first-in-class, breakthrough assets and does not consider re-purposed assets, diagnostics, medical devices or iterative technologies.
The firm prefers to invest early and help take the company through a major inflection point. The firm has no specific management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply